Daniel J. George
Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Daniel J. George

Urology | Hematology | Oncology
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
On Staff At
Offers Telehealth
33 Years of Experience

Distinguished in WT1-Related Wilms Tumor Syndromes
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case.

Dr. George is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

His clinical research consists of co-authoring 320 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Duke University School Of Medicine, 1992
Residency
Internal Medicine, Johns Hopkins Hospital (Maryland)
Specialties
Urology
Hematology
Oncology
Licenses
Urology in NC
Fellowships
Medical Oncology, Johns Hopkins Hospital (Maryland)
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Duke Cancer Center
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-681-6900
Other Locations
Duke Cancer Center Genitourinary (GU) Clinic
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-668-6688
Duke Cancer Center Southpoint
6301 Herndon Rd, Durham, NC 27713
Call: 866-385-3123

Additional Areas of Focus

Dr. George has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Prostate Cancer
Bladder Cancer
Testicular Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: ARN-509, Abiraterone Acetate, Prednisone
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: April 30, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

320 Total Publications

Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Journal: JCO oncology practice
Published: May 02, 2025
View All 320 Publications
Similar Doctors
Michael R. Harrison
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael R. Harrison
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael R. Harrison
Oncology | Hematology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I specialize in treating people with genitourinary (GU) cancers, such as bladder, prostate, testicular and kidney cancer. I don’t treat other types of cancer across the breadth of tumors like some oncologists in the community may, such as blood cancer, breast cancer or lung cancer. My focus has allowed me to gain deep expertise in GU cancers and to stay abreast of the newest treatment advances, clinical research and so on for those specific GU cancers. As a medical oncologist, I meet patients at one of the scariest moments of their lives. I try to help educate them to make a decision about their disease and its process, and what their treatment options may be, so we can come to a shared decision about what might be the best option. The teaching aspect really strikes home for me. Both of my parents are teachers. The root word for “doctor” in Latin means “to teach.” So that is something I’m both naturally called to do and enjoy doing. Dr. Harrison is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Prostatectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mathew C. Raynor
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mathew C. Raynor
Urology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mathew Raynor is an Urologist in Chapel Hill, North Carolina. Dr. Raynor is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Retroperitoneal Fibrosis, Renal Cell Carcinoma (RCC), Intussusception in Children, Nephrectomy, and Reconstructive Urology Surgery. Dr. Raynor is currently accepting new patients.

Sundhar Ramalingam
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sundhar Ramalingam
Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sundhar Ramalingam
Hematology

Duke Cancer Center Cary

216 Ashville Ave, 
Cary, NC 
 (20.1 miles away)
866-385-3123
Experience:
15+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

I mainly treat patients with genitourinary cancers including prostate, kidney, bladder, testicular and penile cancer.  My goal is to be attentive and devoted to my patients who are often dealing with complicated health problems. I try to personalize my care because every patient is different. I believe the future is promising because new treatments are being discovered every day. I am involved in clinical trials done through Duke University.  Clinical trials are designed to provide patients with access to the newest possible treatments. I am also part of our multi-disciplinary cancer team including urologic oncologists, geneticists, radiation oncologists, pathologists, radiologists, and other specialists.  I grew up in Cary and did all of my medical training in the Research Triangle Park area. I feel honored to practice in the same community I have lived in for more than twenty-five years. Dr. Ramalingam is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, and Prostatectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. George's expertise for a condition
ConditionClose
  • Elite
  • Familial Prostate Cancer
    Dr. George is
    Elite
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Prostate Cancer
    Dr. George is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. George is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. George is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. George is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. George is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. George is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Muscle Invasive Bladder Cancer
    Dr. George is
    Distinguished
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Wilms Tumor
    Dr. George is
    Distinguished
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
View All 7 Distinguished Conditions
  • Advanced
  • Bladder Cancer
    Dr. George is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Bone Tumor
    Dr. George is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Nephrectomy
    Dr. George is
    Advanced
    . Learn about Nephrectomy.
    See more Nephrectomy experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. George is
    Advanced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Orchiectomy
    Dr. George is
    Advanced
    . Learn about Orchiectomy.
    See more Orchiectomy experts
  • Urothelial Cancer
    Dr. George is
    Advanced
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
View All 7 Advanced Conditions
  • Experienced
  • Agranulocytosis
    Dr. George is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Brain Tumor
    Dr. George is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Breast Cancer
    Dr. George is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Chronic Familial Neutropenia
    Dr. George is
    Experienced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Inflammatory Breast Cancer
    Dr. George is
    Experienced
    . Learn about Inflammatory Breast Cancer.
    See more Inflammatory Breast Cancer experts
  • Lung Cancer
    Dr. George is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved